

FOSTAMATINIB tablets (Tavlesse® ▼) for treating refractory chronic immune thrombocytopenia

The Pan Mersey Area Prescribing Committee recommends the prescribing of FOSTAMATINIB tablets (Tavlesse® ▼), by specialists only, for treating refractory chronic immune thrombocytopenia in accordance with NICE TA835.

RED

[NICE technology appraisal \(TA\) 835](#) (19 October 2022) updates and replaces [NICE TA759](#) and recommends fostamatinib as an option for treating refractory chronic immune thrombocytopenia (ITP) in adults, only if:

- > they have previously had a thrombopoietin receptor agonist (TPO-RA), or a TPO-RA is unsuitable
- > the company provides fostamatinib according to the commercial arrangement.^[1]

Prescribing and monitoring of therapy must be retained by a specialist in the management of chronic ITP.

Costing information

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population). This is because fostamatinib is a further treatment option for patients who have not had a suitable response to prior therapy including a TPO-RA, or where use of a TPO-RA is not appropriate, and the overall cost of treatment will be similar to the current treatment options.^[2]

References

1. National Institute for Health and Care Excellence. Technology Appraisal 835; [Fostamatinib for treating refractory chronic immune thrombocytopenia](#), 19 October 2022. Accessed online 02 November 2022.
2. National Institute for Health and Care Excellence. Technology Appraisal 835; Resource impact statement: [Fostamatinib for treating refractory chronic immune thrombocytopenia](#), 19 October 2022. Accessed online 02 November 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.